NCI renews UT Southwestern’s $11.5M program of excellence award in kidney cancer

In The Headlines: Private funding can’t replace federal funding—but it can help

In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.

April 09, 2025

Vol.51 No.13

Guest Editorial

Rathmell: We must put the individual at the center of our approach to ending cancer

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

April 04, 2025

Vol.51 No.13

By W. Kimryn Rathmell

In the Archives

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.

April 04, 2025

Vol.51 No.13

Conversation with The Cancer Letter

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

The University of Rochester Wilmot Cancer Institute last week was named the 73rd NCI-designated cancer center. Now, New York State has eight NCI-designated cancer centers. Only California has more—ten.

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.

March 28, 2025

Vol.51 No.12

By Claire Marie Porter and Jacquelyn Cobb

NCI renews UT Southwestern’s $11.5M program of excellence award in kidney cancer

YOU MAY BE INTERESTED IN

In The Headlines: Private funding can’t replace federal funding—but it can help

Rathmell: We must put the individual at the center of our approach to ending cancer

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Renew today!

Subscriber content

Never miss an issue!

Login

NCI renews UT Southwestern’s $11.5M program of excellence award in kidney cancer

YOU MAY BE INTERESTED IN

In The Headlines: Private funding can’t replace federal funding—but it can help

Rathmell: We must put the individual at the center of our approach to ending cancer

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Never miss an issue!

Login

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology